---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Long-term morbidity"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Long-term morbidity. Topics: Comorbidities and consequences of CSU: 2026 international guideline; Autoimmune thyroid disease: systematic review; Thyroid and other autoimmune diseases: 12,778 participants with chronic urticaria in Israel; Other autoimmune diseases: systematic review of prevalence; 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Comorbidities and consequences of CSU: 2026 international guideline

> “In CSU, the most common comorbidities are CIndUs, autoimmune diseases, metabolic syndrome, and allergies. Mental disorders, such as depression and anxiety, sexual dysfunction and sleep disturbance are also common consequences of CSU”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.7-2"></a>

### Autoimmune thyroid disease: systematic review

> “There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%.”
> “Thyroid dysfunction rates are increased in patients with CSU (strong evidence). Hypothyroidism and Hashimoto's thyroiditis are more common than hyperthyroidism and Graves' disease (strong evidence).”
> “Thyroid dysfunction is more common in adult patients with CSU than in children (strong evidence) and in female than in male patients with CSU (weak evidence).”

Source: [Kolkhir et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28407273/)

<a id="topic-2.2.1.7-3"></a>

### Thyroid and other autoimmune diseases: 12,778 participants with chronic urticaria in Israel

> “Data on 12,778 patients given a diagnosis of CU by either allergy or dermatology specialists during 17 years in a large health maintenance organization in Israel were collected.”
> “Having CU was associated with an increased odds ratio for hypothyroidism, hyperthyroidism, and antithyroid antibodies. Female patients with CU had a significantly higher incidence of rheumatoid arthritis, Sjögren syndrome, celiac disease, type I diabetes mellitus, and systemic lupus erythematosus, mostly diagnosed during the 10 years after the diagnosis of CU.”

Source: [Confino-Cohen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22336078/)

<a id="topic-2.2.1.7-4"></a>

### Other autoimmune diseases: systematic review of prevalence

> “The prevalence of individual AIDs in CSU is increased (≥1% in most studies vs ≤1% in the general population).”
> “The rates of comorbidity in most studies were ≥1% for insulin-dependent diabetes mellitus, rheumatoid arthritis (RA), psoriasis and celiac disease (CD), ≥2% for Graves' disease, ≥3% for vitiligo, and ≥5% for pernicious anemia and Hashimoto's thyroiditis.”
> “CSU patients have an increased risk of AIDs, especially adult female patients and those with a positive family history and a genetic predisposition for AIDs, who should be screened for signs and symptoms of AIDs.”

Source: [Kolkhir et al. (2017b)](https://pubmed.ncbi.nlm.nih.gov/29037900/)

<a id="topic-2.2.1.7-5"></a>

### Psychiatric disorders: systematic review and meta-analysis

> “Twenty-five studies were identified. Almost one out of three CU patients have at least one underlying psychiatric disorder. None of the studies clarified whether the psychiatric disorders pre-existed the CU onset, and no association was found between CU severity and duration, and psychological functioning.”
> “After meta-analyzing these three studies, among 177,998 CU patients, 56,258 had psychiatric comorbidity (31.61%). Among 996,446 healthy individuals (control group), 45,471 were found to suffer from at least one psychiatric disorder (4.6%)”
> “The most prevalent were found to be sleep–wake disorders (36.7%), followed by anxiety disorders (30.6%), mood disorders (29.4%), trauma and stressor-related disorders (17.3%), somatic symptom and related disorders (17.2%)”

Source: [Konstantinou and Konstantinou (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6706894/)

<a id="topic-2.2.1.7-6"></a>

### Mental health conditions: United States claims before and after CSU diagnosis

> “Adults (≥18 years) with CSU in the US HealthVerity claims database were included (January 2016-October 2023).”
> “Overall, 224,958 patients were included (mean follow-up: 2.4 years). The proportion of patients with claims for sleep-related conditions increased from baseline to follow-up (8.8% vs 15.4%), and for MH conditions (40.6% vs 56.3%).”
> “Claims for sleep-related and MH conditions increased after CSU diagnosis, particularly among patients with uncontrolled disease”

Source: [Riedl et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43003384/)

<a id="topic-2.2.1.7-7"></a>

### Suicidal ideation and malignant neoplasms: hazard ratios compared with controls

> “Compared with controls, patients with CSU exhibited higher risk and rates of the leading causes of death in the United States, including suicidal ideations/suicide attempts (HR 3.14, 95% CI 3.00-3.28) and malignant neoplasms (HR 2.09, 95% CI 2.02-2.16).”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.7-8"></a>

### Corticosteroid-associated adverse events: United States claims cohort of 200,298 participants

> “This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).”
> “Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.”
> “The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.”
> “When assessed according to corticosteroid user type, lipid disorders were the most common AE among patients in the ≤ 31D group (33.0%), and hypertension was the most frequent in the > 31 to ≤ 60D, > 60D, and ≥ 90Dc groups (38.0%, 44.0%, and 49.4%, respectively)”
> “The proportions of patients who reported skeletal conditions and avascular necrosis were ≥ 3 times higher in the ≥ 90Dc group versus non-users.”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.1.7-9"></a>

### Prolonged systemic corticosteroid use: 2026 international guideline

> “If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children). Because such high doses will have side effects over the long term, we strongly recommend against the prolonged use of corticosteroids.”
> “We recommend against the long‐term use of systemic glucocorticosteroids or depot preparations in CU.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
